Daily biotech dealflow + market tape in 5 minutes — for VC, BD&L, and public biotech investors.
Newsletter
Oct 13, 2026
•
5 min read
Plus a first-in-class herpes approval, an alpha-emitter Phase 3 win, and three biotechs queuing for IPOs.
Oct 9, 2026
Plus Zealand’s amylin data in diabetes, Tukysa moves up a line, and TRexBio prices at $14.
Oct 8, 2026
4 min read
Plus Halozyme blocks SC Keytruda in eight countries, and Caribou pulls the plug.
Oct 7, 2026
Plus Epkinly's frontline DLBCL win and ArriVent's 57% plunge.
Oct 6, 2026
Vaxcyte's pivotal print sent PCVX flying, Shionogi paid $2B for IntraBio, and Genentech bought Alector a runway.
Oct 5, 2026
Lilly takes Jaypirca first-line, and a sell-side desk crowns Genmab’s ovarian ADC.
Oct 2, 2026
Survodutide wins Phase 3 and still disappoints, while Lilly walks away from Foghorn.
Oct 1, 2026
Plus Lilly's amylin cocktail edges its own triple-G, and a liver death shadows Bristol's fibrosis bet.
Sep 30, 2026
Year-four Huntington's data wobbles, full TRIUMPH-2 lands at EASD, and Merck's TL1A clears HS.
